Find it in seconds.
Sectors Tags Blog
ISRG
30 filings
Timeline Columns Start Research 8-K Categories
2025
Q4 2 filings
Oct 22
Q3 2025 Results
Financial data not available in provided content
10-Q View →
Oct 21
Q3 Earnings
Q3 2025 financial results for quarter ended Sep 30, 2025
8-K View →
Q3 2 filings
Jul 23
Q2 2025 Results
Financial data not available in provided XBRL structure
10-Q View →
Jul 22
Q2 2025 Earnings
Q2 2025 financial results announced
8-K View →
Q2 4 filings
May 15
CEO Transition
David Rosa appointed CEO July 1, Gary Guthart becomes Executive Chair
8-K View →
May 5
Annual Meeting & Share Buyback
$4.0B share repurchase authorized, 5M shares added to incentive plan
8-K View →
Apr 23
Q1 2025 Results
Rev $2.25B (+19.2% YoY), EPS $1.92 (+27.2% YoY)
10-Q View →
Apr 22
Q1 2025 Earnings
Q1 2025 financial results announced
8-K View →
Q1 5 filings
Mar 14
2025 Proxy Statement
2024 revenue: $8.35B (+17% YoY), Net income +29% YoY, 2.7M+ procedures performed
DEF 14A View →
Jan 31
FY2024 2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL data
📌 Company filed FY2024 10-K on January 31, 2025 with comprehensive financial disclosures including revenue segmentation by domestic/international markets and product/service categories
10-K View →
Jan 23
Q4 Earnings + Acquired EU Distribution
€290M upfront + €31M milestones for EU distributors
8-K View →
Jan 15
Q4 2024 Earnings
Preliminary Q4 and full year 2024 results announced
8-K View →
Jan 6
CFO and CCO Promotions
Samath salary $605K→$683K, Charlton $600K→$670K, both bonus targets 65%→100%
8-K View →
2024
Q4 2 filings
Oct 18
Q3 2024 Results
Financial data not clearly extractable from provided XBRL format
10-Q View →
Oct 17
Q3 2024 Earnings
Q3 2024 financial results announced
8-K View →
Q3 3 filings
Jul 25
Board Appointment
David J. Rosa appointed to Board, size increased to 12 members
8-K View →
Jul 19
Q2 2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL data
10-Q View →
Jul 18
Q2 2024 Earnings
Financial results for quarter ended June 30, 2024
8-K View →
Q2 3 filings
Apr 30
Annual Shareholder Meeting Results
All 11 directors elected, pay equity proposal rejected
8-K View →
Apr 19
Q1 2024 Results
Rev $1.89B (+11.5% YoY), EPS $1.51 (+51% YoY)
10-Q View →
Apr 18
Q1 2024 Earnings
Q1 2024 financial results announced
8-K View →
Q1 5 filings
Mar 14
FDA Clears da Vinci 5 System
Fifth-generation robotic surgical system approved
8-K View →
Mar 8
2024 Proxy Statement
Annual Meeting: April 25, 2024, Record Date: Feb 29, 2024, Shares Outstanding: 354.4M
DEF 14A View →
Jan 31
FY2023 Results
Unable to extract specific revenue/EPS figures from provided XBRL metadata
📌 Unable to identify specific milestone from provided XBRL metadata - actual financial statement content needed
10-K View →
Jan 23
Q4 2023 Earnings
Financial results for quarter ended December 31, 2023
8-K View →
Jan 9
Q4 2023 Preliminary Results
Preliminary Q4 and full year 2023 financial results announced
8-K View →
2023
Q4 3 filings
Oct 31
Board Appointment
Sreelakshmi Kolli appointed to Board, increased to 12 members
8-K View →
Oct 20
Q3 2023 Results
Financial data not extractable from provided metadata
10-Q View →
Oct 19
Q3 2023 Earnings
Financial results for quarter ended September 30, 2023
8-K View →
Q3 1 filings
Jul 24
Q2 2023 Results
Financial data not clearly extractable from XBRL format provided
10-Q View →
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.